Endocarditis  >>  Cubicin (daptomycin)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT00401960: Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.

Terminated
4
6
US
Daptomycin, Cubicin
Weill Medical College of Cornell University
Endocarditis, Bacterial
10/08
10/08
STOP-NT, NCT01734694: Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

Terminated
4
100
US
Vancomycin, Ceftaroline, Teflaro, Daptomycin, Cubicin, Linezolid, Zyvox
Henry Ford Health System
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
09/12
09/12

Download Options